v3.26.1
Segments of Business (Tables)
 3 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Information
Financial information relating to the Company’s reportable segments and reconciliations to the consolidated totals was as follows:
Three Months Ended June 30,
(In millions)20262025
Segment revenues (1)
North American Pharmaceutical$86,773 $82,729 
Oncology & Multispecialty14,222 10,658 
Prescription Technology Solutions1,566 1,434 
Medical-Surgical Solutions2,819 2,701 
Other— 305 
Total revenues$105,380 $97,827 
Other segment expense, net (2)
North American Pharmaceutical (3)
$85,870 $82,135 
Oncology & Multispecialty13,897 10,446 
Prescription Technology Solutions (4)
1,340 1,181 
Medical-Surgical Solutions (5)
2,697 2,480 
Other— 292 
Total other segment expense, net$103,804 $96,534 
Segment operating profit
North American Pharmaceutical$903 $594 
Oncology & Multispecialty325 212 
Prescription Technology Solutions226 253 
Medical-Surgical Solutions122 221 
Other— 13 
Subtotal1,576 1,293 
Corporate expenses, net (6)
(191)(193)
Interest expense(77)(49)
Income before income taxes$1,308 $1,051 
Segment depreciation and amortization (7)
North American Pharmaceutical$39 $32 
Oncology & Multispecialty66 42 
Prescription Technology Solutions19 21 
Medical-Surgical Solutions26 22 
Other— 3 
Corporate45 37 
Total segment depreciation and amortization$195 $157 
Segment expenditures for long-lived assets (8)
North American Pharmaceutical$64 $61 
Oncology & Multispecialty18 24 
Prescription Technology Solutions— 1 
Medical-Surgical Solutions27 25 
Other— 1 
Corporate43 77 
Total segment expenditures for long-lived assets$152 $189 
(1)Revenues from services on a disaggregated basis represent less than 1% of the North American Pharmaceutical segment’s total revenues, approximately 7% of the Oncology & Multispecialty segment’s total revenues, approximately 39% of the Prescription Technology Solutions segment’s total revenues, and less than 1% of the Medical-Surgical Solutions segment’s total revenues. The Company’s Norwegian operations were included in Other.
(2)Other segment expense, net includes cost of sales, total operating expenses, as well as other income, net, for the Company’s reportable segments.
(3)The Company’s North American Pharmaceutical other segment expense, net includes the following:
•related to the bankruptcy of the Company’s customer Rite Aid Corporation (including certain of its subsidiaries, “Rite Aid”), the Company recorded a provision for bad debts of $189 million during the three months ended June 30, 2025. This was recorded within “Selling, distribution, general, and administrative expenses” in the Company’s Condensed Consolidated Statements of Operations.
(4)The Company’s Prescription Technology Solutions other segment expense, net includes the following:
•restructuring charges of $61 million for the three months ended June 30, 2026 for restructuring initiatives as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net.”
(5)The Company’s Medical-Surgical Solutions other segment expense, net includes the following:
•charges of $45 million for the three months ended June 30, 2026 related to the planned separation of the Medical-Surgical Solutions business.
(6)Corporate expenses, net include the following:
•restructuring charges of $50 million and $29 million for the three months ended June 30, 2026 and 2025, respectively, for restructuring initiatives as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net;”
•a credit of $34 million for the three months ended June 30, 2026 related to the estimated liability for opioid related claims, as discussed in Financial Note 11, “Commitments and Contingent Liabilities;” and
•charges of $23 million for the three months ended June 30, 2026 related to the planned separation of the Medical-Surgical Solutions business.
(7)Amounts primarily consist of amortization of acquired intangible assets purchased in connection with business acquisitions and capitalized software for internal use as well as depreciation and amortization of property, plant, and equipment, net.
(8)Long-lived assets consist of property, plant, and equipment, net and capitalized software.
Schedule of Long-lived Assets By Geographic Areas
Long-lived assets by geographic areas were as follows:
(In millions)June 30, 2026March 31, 2026
Long-lived assets
United States$3,185 $3,177 
Foreign244 255 
Total long-lived assets$3,429 $3,432